(Q30445663)

English

A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

21 June 2017

A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study (English)

1 reference

Europe PubMed Central

21 June 2017

peritoneal carcinoma

1 reference

based on heuristic

inferred from title

gynecologic oncology

1 reference

based on heuristic

inferred from title

author name string

Susan C Modesitt

1

1 reference

Europe PubMed Central

21 June 2017

Michael Sill

2

1 reference

Europe PubMed Central

21 June 2017

James S Hoffman

3

1 reference

Europe PubMed Central

21 June 2017

David P Bender

4

1 reference

Europe PubMed Central

21 June 2017

Gynecologic Oncology Group

5

1 reference

Europe PubMed Central

21 June 2017

language of work or name

0 references

publication date

4 March 2008

1 reference

Europe PubMed Central

21 June 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

21 June 2017

109

1 reference

Europe PubMed Central

21 June 2017

182-186

1 reference

Europe PubMed Central

21 June 2017

2

1 reference

Europe PubMed Central

21 June 2017

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.009

7 January 2021

The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.009

7 January 2021

Histone deacetylase inhibitors promote apoptosis and differential cell cycle arrest in anaplastic thyroid cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.009

7 January 2021

Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.009

7 January 2021

Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.009

7 January 2021

Histone deacetylase inhibitors require caspase activity to induce apoptosis in lung and prostate carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.009

7 January 2021

Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.009

7 January 2021

In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.009

7 January 2021

Evaluation of cisplatin and cyclosporin A in recurrent platinum-resistant ovarian cancer: a phase II study of the gynecologic oncology group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.009

7 January 2021

Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.009

7 January 2021

Phase II trial of pyrazoloacridine in recurrent platinum-resistant ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.009

7 January 2021

Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.009

7 January 2021

Phase II trial of CI-958 in recurrent platinum-refractory ovarian carcinoma. A Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.009

7 January 2021

Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A Gynecologic Oncology Group trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.009

7 January 2021

Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.009

7 January 2021

Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.009

7 January 2021

Optimal flexible designs in phase II clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.009

7 January 2021

Anticancer activities of histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.009

7 January 2021

Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.009

7 January 2021

Defining the chemotherapeutic targets of histone deacetylase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.009

7 January 2021

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.009

7 January 2021

Histone deacetylase inhibitors: biology and mechanism of action

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.009

7 January 2021

Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.009

7 January 2021

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.009

7 January 2021

Identifiers

10.1016/J.YGYNO.2008.01.009

1 reference

Europe PubMed Central

21 June 2017

1 reference

Europe PubMed Central

21 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30445663&oldid=1946756297"